March 17, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq ... in patients with immune checkpoint inhibitor (ICI) -refractory advanced or metastatic solid tumors. Interim results ...

TG Therapeutics (TGTX) announced the presentation of data highlighting BRIUMVI in patients with relapsing forms of multiple sclerosis, at the ...

On Tuesday, Indaptus Therapeutics, Inc. (NASDAQ:INDP) announced it advanced to a new expansion arm of its Phase 1b/2 clinical trial of Decoy20. The expansion will evaluate the combination of ...

About Vividion Vividion Therapeutics, Inc., a wholly owned and independently operated subsidiary of Bayer AG, is a clinical stage biopharmaceutical company utilizing novel discovery technologies ...

yet traditionally undruggable targets with precision small-molecule therapeutics SAN DIEGO & BERLIN--(BUSINESS WIRE)--Vividion Therapeutics, Inc. (Vividion) today announced that the first patient ...

Indaptus began a new expansion phase of its Decoy20 trial, combining it with BeiGene’s tislelizumab to assess safety and anti-tumor activity The company expects its cash reserves to fund ...

Plus Therapeutics shares are trading higher by 244% during Thursday's session. The company announced that the FDA accepted the name REYOBIQ for the company's lead asset. The ‘Trade of the Day ...

Out of the shadows, new CDMO Artis BioSolutions has decloaked on a mission to tackle the tricky production process for advanced therapeutics. Artis officially emerged from stealth on Wednesday ...

Peptris has a pipeline of advanced preclinical assets in rare diseases, alopecia, inflammation and oncology. We are confident that Revio Therapeutics’ expertise in repurposing medicines will ...